Patents by Inventor Roy M. Vijesurier

Roy M. Vijesurier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis B virus typing and resistance assay
    Patent number: 10526667
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 7, 2020
    Assignee: ABBOTT MOLECULAR INC.
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang
  • HEPATITIS B VIRUS TYPING AND RESISTANCE ASSAY
    Publication number: 20150259755
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Application
    Filed: April 30, 2015
    Publication date: September 17, 2015
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang
  • Hepatitis B virus typing and resistance assay
    Patent number: 9045803
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 2, 2015
    Assignee: Abbott Molecular Inc.
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang
  • HEPATITIS B VIRUS TYPING AND RESISTANCE ASSAY
    Publication number: 20130252232
    Abstract: The present invention provides methods, kits, and oligonucleotides for detecting and analyzing the nucleotide sequence of a reverse transcriptase (RT) region of the polymerase (Pol) gene of Hepatitis B Virus (HBV). In certain embodiments, a target RT region is amplified and subjected to DNA sequencing. The sequence obtained is compared to one or more DNA sequences characteristic of an HBV genotype or serotype, and/or one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine, to determine the HBV genotype or serotype of the amplified product and/or the presence or absence of one or more DNA sequences characteristic of an HBV mutation that confers resistance to a drug or vaccine.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 26, 2013
    Applicant: ABBOTT MOLECULAR INC.
    Inventors: Gregor W. Leckie, Reuben J. Ofsaiof, Roy M. Vijesurier, Hong Wang